LB-002 - SHORT DAILY DISCONNECT OF FIRST-IN-CLASS BiTE® BLINATUMOMAB CONTINUOUS INTRAVENOUS INFUSION (cIV) TO IMPROVE PATIENT QUALITY OF LIFE WHILE MINIMIZING IMPACT ON EXPOSURE AND EFFICACY IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS.
F. Chandra1, H. Wong2, G. Zugmaier3, K. Velasco1, S. Doshi1, S. Dutta1, V. Upreti2; 1Amgen, Thousand Oaks, CA, USA, 2Amgen, South San Francisco, CA, USA, 3Amgen, Munich, Germany.
.jpg "Fiona A. Chandra, PhD photo")
.png)